The National Institutes of Health’s Post

It's important to participate in research.

Apologies for incorrect link. This is the correct one: https://lnkd.in/ePMAcGH2 We have corrected it in the original post as well.

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome. Read the full news release here - https://bit.ly/4cBc7x5 #innovativedesign #innovation #InnovateWithUs #visitnorfolk #visitvirginia #Virginia #norfolkva #norfolkinnovation

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis and is a major cause of morbidity and mortality. Patients with active pulmonary TB may be asymptomatic, have mild or progressive dry cough, or present with multiple symptoms, including fever, fatigue, weight loss, night sweats, and a cough that produces bloody sputum. If TB is detected early and fully treated, people with the disease quickly become non-infectious and eventually cured. Visit our journal website for more updates: https://lnkd.in/dQ84mS8f (Source: Internet) Submissions are open for upcoming issue! Submit your manuscript to: immunologyallergy@maplejournal.com #pulmonarytuberculosis #sputum #lungs #allergy #drycough #immunology #fatigue

Pharmaceuticals should all be investigated after the global fraud of “vaccines” and any research being done along with levels of danger of research vs no research. A list of all countries participating in contagious diseases needs to be made public and under strict guidelines with zero tolerance regarding outbreaks. Why do we have an FDA when they will not test and the house committee on Energy and Commerce is investigating? And side note: If an injection does not give immunity then it should not be called a vaccine. It seems we have experienced this with flu, shingles, covid, pneumonia and probably others! How many vaccines are we pumping into our innocent infants? The USA uses more pharmaceuticals than the world combined! Why is that?

🔬 Great Resource for all Researchers! 🔍 Calling all researchers in the field of infectious diseases, allergies, and immune-mediated diseases! The NIAID Office of Data Science and Emerging Technologies is proud to introduce the **NIAID Data Ecosystem Discovery Portal** – your new go-to resource for cutting-edge data. 🌐 **Unlocking a World of Data** With over 2.8 million resources at your fingertips, this portal is your gateway to a vast and diverse ecosystem of infectious disease, allergy, and immune-mediated disease datasets. Whether you're a seasoned scientist or a budding researcher, these resources are here to supercharge your studies. 📈 **Why It Matters** In today's research landscape, access to quality data is crucial. The NIAID Data Ecosystem Discovery Portal offers you: 1. **Diverse Datasets**: Explore an extensive collection of datasets covering a wide range of topics, ensuring you find the perfect fit for your research. 2. **Precision and Relevance**: Filter and search tools help you pinpoint the exact data you need, saving you valuable time. 3. **Collaboration Opportunities**: Connect with fellow researchers, fostering collaboration and knowledge exchange. 4. **Stay Current**: Stay on the cutting edge of your field with access to the latest data resources. 💡 **How to Get Started** Getting started is a breeze: 1. Visit the NIAID Data Ecosystem Discovery Portal website. 2. Register for an account to access advanced features. 3. Explore, search, and discover the wealth of data resources at your disposal. 🌟 **Join the Research Revolution** With the NIAID Data Ecosystem Discovery Portal, you're not just accessing data; you're joining a community of passionate researchers dedicated to advancing our understanding of infectious diseases, allergies, and immune-mediated diseases. Don't miss out on this game-changing resource – it's time to elevate your research to new heights! 🚀 #Research #DataScience #InfectiousDiseases #Allergies #ImmuneSystem #NIAID #DataPortal

💉 Inhalon Biopharma has been awarded a $1,020,000 grant by the Department of Health and Human Services, specifically from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. This funding supports the development of IN-007, an inhaled muco-trapping immunotherapy for COVID-19 and other ACE2-targeted infections. The project aims to produce a GLP batch of IN-007, conduct IND-enabling studies, and test efficacy in vivo and ex vivo. The research, starting on 3/1/24 and lasting nearly 3 years until 2/28/27, focuses on a treatment that can be self-administered, reduces hospitalization risk, and retains activity against all variants. #SBIR #STTR #HealthInnovation #COVID19

Influenza vaccine Influenza is a respiratory disease resulting from infection with the influenza virus. It is more prevalent during cold periods, with the peak of infections between November and April in the Northern Hemisphere and between June and October in the Southern Hemisphere. The influenza virus is highly transmissible in humans . The World Health Organization (WHO) estimates that there are 1 billion cases of influenza worldwide each year, of which 3–5 million are severe cases. An estimated 650,000 deaths per year result from influenza infection The most effective way to prevent influenza infection is through vaccination Seasonal flu vaccination campaigns represent a major investment for countries and governments. It is therefore important to assess the effectiveness

The National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, will conduct a trial comparing the administration of Vaccigen's parent company Ocugen’s mucosal vaccine candidate, OCU500, via two different mucosal routes, inhalation into the lungs and as a nasal spray. The announced collaboration comes at a time when COVID-19 infection rates are rising with the emergence of new variants. We look forward to this important next step in the development of our novel mucosal vaccine platform and further supporting the Company’s commitment to advancing public health. Read more at https://ow.ly/hYeG50PViX7

In this piece I’m quoted about how — with tools like vaccines and Paxlovid — #COVID19 is becoming on par with influenza and other respiratory viruses https://lnkd.in/evZBqCm7